212 patents
Page 10 of 11
Utility
Biodegradable Lipids for Delivery of Nucleic Acids
15 Jul 20
Frank DeRosa, Michael Heartlein
Filed: 21 Nov 19
Utility
Composition and Methods for Treatment of Primary Ciliary Dyskinesia
8 Jul 20
The present invention provides, among other things, methods and compositions for treating primary ciliary dyskinesia (PCD) based on mRNA therapy.
Anusha Dias, Darshan Parekh, Jeffrey S. Dubins, Christian Cobaugh, Shrirang Karve, Zarna Patel, Sara J. Dunaj, Frank DeRosa, Michael Heartlein
Filed: 6 Jan 20
Utility
Cleavable lipids
6 Jul 20
Disclosed herein are novel compounds, pharmaceutical compositions comprising such compounds and related methods of their use.
Braydon Charles Guild, Michael Heartlein, Frank DeRosa, Jerry Chi Zhang
Filed: 24 Jun 19
Utility
Multimeric oligonucleotide compounds
6 Jul 20
The disclosure provides multimeric oligonucleotide compounds, comprising two or more target-specific oligonucleotides (e.g., antisense oligonucleotides (ASOs)), each being resistant to cleavage, and linked together by a cleavable linker.
Eugen Uhlmann, Markus Weber, Romesh R. Subramanian, Thomas Dino Rockel, Arthur M. Krieg
Filed: 29 Aug 18
Utility
Multimeric Coding Nucleic Acid and Uses Thereof
3 Jun 20
The present invention provides, among other things, multimeric coding nucleic acids that exhibit superior stability for in vivo and in vitro use.
Frank DeRosa, Michael Heartlein, Daniel Crawford, Shrirang Karve
Filed: 13 Aug 19
Utility
Ice-based Lipid Nanoparticle Formulation for Delivery of Mrna
20 May 20
The present invention provides, among other things, compositions and methods of formulating nucleic acid-containing nanoparticles comprising no more than three distinct lipids components, one distinct lipid component being a sterol-based cationic lipid.
Frank DeRosa, Michael Heartlein, Shrirang Karve
Filed: 26 Jan 20
Utility
TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF NEBULIZED mRNA ENCODING CFTR
20 May 20
The present invention provides, among other things, an improved method of treating cystic fibrosis (CF) in a human subject.
SHRIRANG KARVE, FRANK DEROSA, MICHAEL HEARTLEIN, ZARNA PATEL
Filed: 20 Nov 19
Utility
Methods and Compositions for Delivering Mrna Coded Antibodies
20 May 20
The present invention provides, among other things, methods and compositions for delivering an antibody in vivo by administering to a subject in need thereof one or more mRNAs encoding a heavy chain and a light chain of an antibody, and wherein the antibody is expressed systemically in the subject.
Michael Heartlein, Frank DeRosa, Anusha Dias, Braydon Charles Guild
Filed: 23 Jan 20
Utility
Compositions and methods for modulating MECP2 expression
18 May 20
Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of MECP2.
Arthur M. Krieg, Romesh Subramanian, James McSwiggen, Jeannie T. Lee
Filed: 18 Oct 17
Utility
Synergistic enhancement of the delivery of nucleic acids via blended formulations
11 May 20
Disclosed herein are pharmaceutical compositions that comprise “blends” of lipid nanoparticles and related methods of using such blended compositions to deliver polynucleotides to one or more target cells, tissues or organs.
Frank DeRosa, Lianne Smith, Michael Heartlein, Braydon Charles Guild
Filed: 9 Oct 18
Utility
Quantitative assessment for cap efficiency of messenger RNA
20 Apr 20
The present invention provides, among other things, methods of quantitating mRNA capping efficiency, particularly mRNA synthesized in vitro.
Michael Heartlein, Frank DeRosa, Anusha Dias
Filed: 13 Mar 14
Utility
Methods for Purification of Messenger Rna
25 Mar 20
The present invention provides, among other things, methods for purifying mRNA based on normal flow filtration for therapeutic use.
Joseph Parella, Kimberly Gillis, Jonathan Abysalh, Travis Jeannotte, Erik Held, Frank DeRosa, Michael Heartlein, Rebecca Powell
Filed: 25 Aug 19
Utility
Process of Preparing Mrna-loaded Lipid Nanoparticles
18 Mar 20
The present invention provides an improved process for lipid nanoparticle formulation and mRNA encapsulation.
Shrirang Karve, Zarna Patel, Yi Zhang, Ashish Sarode, Rebecca L. Ball, Frank DeRosa, Michael Heartlein
Filed: 27 Aug 19
Utility
Lipid Nanoparticle Compositions and Methods for Mrna Delivery
18 Mar 20
Disclosed herein are compositions and methods for modulating the production of a protein in a target cell.
Braydon Charles Guild, Frank DeRosa, Michael Heartlein
Filed: 11 Nov 19
Utility
Lipid Formulations for Delivery of Messenger Rna
11 Mar 20
Michael Heartlein, Daniel Anderson, Yizhou Dong, Frank DeRosa
Filed: 14 Nov 19
Utility
Methods and compositions for delivering mRNA coded antibodies
9 Mar 20
The present invention provides, among other things, methods and compositions for delivering an antibody in vivo by administering to a subject in need thereof one or more mRNAs encoding a heavy chain and a light chain of an antibody, and wherein the antibody is expressed systemically in the subject.
Michael Heartlein, Frank DeRosa, Anusha Dias, Braydon Charles Guild
Filed: 11 Sep 18
Utility
Liver specific delivery of messenger RNA
2 Mar 20
Disclosed herein are compositions and methods of modulating the expression of gene or the production of a protein by transfecting target cells with nucleic acids.
Frank DeRosa, Michael Heartlein
Filed: 5 Apr 16
Utility
CFTR Mrna Compositions and Related Methods and Uses
12 Feb 20
Materials, formulations, production methods, and methods for delivery of CFTR mRNA for induction of CFTR expression, including in the mammalian lung are provided.
Michael Heartlein, Braydon Charles Guild, Frank DeRosa, Carsten Rudolph, Christian Plank, Lianne Smith
Filed: 13 Aug 19
Utility
Ice-based Lipid Nanoparticle Formulation for Delivery of Mrna
5 Feb 20
The present invention provides, among other things, compositions and methods of formulating nucleic acid-containing nanoparticles comprising no more than three distinct lipids components, one distinct lipid component being a sterol-based cationic lipid.
Frank DeRosa, Michael Heartlein, Shrirang Karve
Filed: 10 Oct 19
Utility
Dry Powder Formulations for Messenger Rna
22 Jan 20
The present invention provides stable, dry powder messenger RNA formulations for therapeutic use, and methods of making and using the same.
Shrirang Karve, Frank DeRosa, Michael Heartlein, Zarna Patel, Ashish Sarode
Filed: 22 Jul 19